Literature DB >> 23910904

Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients.

Marius Ilie1, Véronique Hofman, Joséphine Zangari, Johanna Chiche, Jérôme Mouroux, Nathalie M Mazure, Jacques Pouysségur, Patrick Brest, Paul Hofman.   

Abstract

The disorganized neo-vasculature in tumours causes fluctuations in the concentration of oxygen, which contributes to tumour development and metastatic potential. Although hypoxic regulation of the expression of the carbonic anhydrases CAIX and CAXII is well established, the effect of re-oxygenation on these proteins remains to be elucidated. A549 and H1975 human lung cancer cell lines were exposed to hypoxia for 24 h and then re-oxygenated. CAIX or CAXII expression and cell cycle progression at different time-points were monitored. A549-shCA9 cells were analyzed for cell cycle progression in the same conditions. We demonstrate for the first time an association between the stability of CAIX and restoration of the S/G2 phase of hypoxia-arrested cells subjected to re-oxygenation. In exchange, we have found that the loss of CA9 did not cause a decreased progression into S/G2 phase during re-oxygenation, but rather affected the hypoxic growth arrest. We previously demonstrated that CAIX expression is a poor prognostic factor and that CAXII expression is a good prognostic factor in non-small cell lung cancer (NSCLC) patients. We further detail the relevance of the combined expression of these proteins for predicting outcome in a large population of NSCLC patients after long-term follow-up. The high CAIX/low CAXII expression sub-group was associated with a high cumulative incidence of relapse and with poor overall survival of NSCLC patients (P < 0.0001). Our results demonstrate a critical role for re-oxygenation on CAIX and CAXII levels that may select for an aggressive lung cancer phenotype. These findings suggest that CAIX and CAXII play dual roles in tumour progression and emphasize their significant prognostic and potential therapeutic value.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Carbonic anhydrase IX; Carbonic anhydrase XII; NSCLC; Prognosis; Re-oxygenation

Mesh:

Substances:

Year:  2013        PMID: 23910904     DOI: 10.1016/j.lungcan.2013.07.005

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.

Authors:  Jian Chen; Lijuan Hu; Fan Zhang; Junjun Wang; Jie Chen; Yumin Wang
Journal:  Oncol Lett       Date:  2017-08-10       Impact factor: 2.967

2.  Saccharin: a lead compound for structure-based drug design of carbonic anhydrase IX inhibitors.

Authors:  Brian P Mahon; Alex M Hendon; Jenna M Driscoll; Gregory M Rankin; Sally-Ann Poulsen; Claudiu T Supuran; Robert McKenna
Journal:  Bioorg Med Chem       Date:  2014-12-23       Impact factor: 3.641

3.  Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer.

Authors:  Ilke Tunali; Yan Tan; Jhanelle E Gray; Evangelia Katsoulakis; Steven A Eschrich; James Saller; Hugo J W L Aerts; Theresa Boyle; Jin Qi; Albert Guvenis; Robert J Gillies; Matthew B Schabath
Journal:  JNCI Cancer Spectr       Date:  2021-05-13

4.  The Carbonic Anhydrase Inhibitor E7070 Sensitizes Glioblastoma Cells to Radio- and Chemotherapy and Reduces Tumor Growth.

Authors:  Silvia A Teixeira; Mariano S Viapiano; Augusto F Andrade; Mohan S Nandhu; Julia A Pezuk; Lucas T Bidinotto; Veridiana K Suazo; Luciano Neder; Carlos G Carlotti; Aline P Becker; Luiz Gonzaga Tone; Carlos A Scrideli
Journal:  Mol Neurobiol       Date:  2021-06-03       Impact factor: 5.590

5.  Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Fumiaki Ochi; Atsushi Shiozaki; Daisuke Ichikawa; Hitoshi Fujiwara; Shingo Nakashima; Kenichi Takemoto; Toshiyuki Kosuga; Hirotaka Konishi; Shuhei Komatsu; Kazuma Okamoto; Mitsuo Kishimoto; Yoshinori Marunaka; Eigo Otsuji
Journal:  J Cancer       Date:  2015-07-29       Impact factor: 4.207

Review 6.  pH sensing and regulation in cancer.

Authors:  Mehdi Damaghi; Jonathan W Wojtkowiak; Robert J Gillies
Journal:  Front Physiol       Date:  2013-12-17       Impact factor: 4.566

7.  Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.

Authors:  Zhihong Zhao; Guixiang Liao; Yongqiang Li; Shulu Zhou; Hequn Zou; Samitha Fernando
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

8.  Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1.

Authors:  Marie E Beckner; Ian F Pollack; Mary L Nordberg; Ronald L Hamilton
Journal:  BBA Clin       Date:  2015-11-10

9.  Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.

Authors:  Andrea Orue; Valery Chavez; Mary Strasberg-Rieber; Manuel Rieber
Journal:  BMC Cancer       Date:  2016-11-18       Impact factor: 4.430

10.  Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Authors:  Kevin Washetine; Simon Heeke; Christelle Bonnetaud; Mehdi Kara-Borni; Marius Ilié; Sandra Lassalle; Catherine Butori; Elodie Long-Mira; Charles Hugo Marquette; Charlotte Cohen; Jérôme Mouroux; Eric Selva; Virginie Tanga; Coraline Bence; Jean-Marc Félix; Loic Gazoppi; Taycir Skhiri; Emmanuelle Gormally; Pascal Boucher; Bruno Clément; Georges Dagher; Véronique Hofman; Paul Hofman
Journal:  Cancers (Basel)       Date:  2018-06-29       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.